Clinical Read2026-10-13
BMF-650 (GLP-131)
Biomea Fusion Inc.BMEA
- Indication
- Obesity
- Stage
- phase1
- Event
- Initial Data
- Details
October 12, 2026: Biomea Fusion, Inc. (NASDAQ: BMEA) announced it will report results on October 13, 2026 from its Phase I GLP-131 clinical study of BMF-650, an investigational next-generation oral small-molecule GLP-1 receptor agonist. The company said management will discuss the results during a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) on October 13, 2026. The release identifies BMF-650 and icovamenib as the company’s oral small-molecule programs for diabetes and obesity. No study data were included in this announcement.
- Source
- View catalyst source ↗